Triple-Negative Breast Cancer Treatment Algorithm : Episode 3

Navigation of Triple-Negative Breast Cancer Treatment Toxicities

February 10, 2025

Opinion

Video

Panelists discusses how triple-negative breast cancer (TNBC) treatment toxicities require careful monitoring and management. Common adverse effects include fatigue, nausea, hair loss, neuropathy from chemotherapy, and radiation-induced skin changes. Health care teams employ preventive strategies, dose modifications, and supportive care to minimize complications while maintaining treatment efficacy.

EP: 1.Early-Stage Triple-Negative Breast Cancer

EP: 2.Locally Advanced Triple-Negative Breast Cancer

Now Viewing

EP: 3.Navigation of Triple-Negative Breast Cancer Treatment Toxicities

EP: 4.Approach to Metastatic Disease

EP: 5.Clinical Pros of Sacituzumab and T-DXd

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore

April 17th 2025

Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber, MD, MPH

November 15th 2017

Podcast

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC

Kristie L. Kahl

April 22nd 2024

Article

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Peter Schmid, MD

April 7th 2017

Podcast

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC

Ariana Pelosci

March 22nd 2024

Article

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

Russ Conroy

February 13th 2024

Article

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Related Content

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore

April 17th 2025

Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber, MD, MPH

November 15th 2017

Podcast

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC

Kristie L. Kahl

April 22nd 2024

Article

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Peter Schmid, MD

April 7th 2017

Podcast

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC

Ariana Pelosci

March 22nd 2024

Article

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue